India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial first-in-human studies abroad. Other nations like the US and Australia offer faster approval processes for trials. China now leads in novel medicine development due to its streamlined regulatory environment. Reforming India's system can unlock its potential in novel drug innovation.
Recommended for you
